Treatment progress of relapsed/refractory diffuse large B-cell lymphoma / 白血病·淋巴瘤
Journal of Leukemia & Lymphoma
; (12): 716-720,724, 2018.
Artigo
em Chinês
| WPRIM (Pacífico Ocidental)
| ID: wpr-732664
Biblioteca responsável:
WPRO
ABSTRACT
Patients with relapsed/refractory (R/R) diffuse large B-cell lymphoma (DLBCL) after two or more lines of therapy and who are not candidates for stem cell transplantation have limited effective treatment options, resulting in a poor prognosis, thus, treatments with novel mechanisms of action are urgently needed. In the 60th American Society of Hematology (ASH) Annual Meeting, detailed reports focused on the research progresses of single agent, drug combination and chimeric antigen receptor T cell (CAR-T) therapy, providing more treatment options for R/R DLBCL patients.
Texto completo:
Disponível
Base de dados:
WPRIM (Pacífico Ocidental)
Idioma:
Chinês
Revista:
Journal of Leukemia & Lymphoma
Ano de publicação:
2018
Tipo de documento:
Artigo